ANTX
AN2 Therapeutics·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 1
Bearish signal 3
Ample Liquidity
Price Hits New Low
Price Hits 52-week Low
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ANTX
An2 Therapeutics, Inc.
A biopharmaceutical company focused on developing treatments for infectious diseases and cancer
1800 El Camino Real, Suite D, Menlo Park, California 94027
--
AN2 Therapeutics, Inc., was incorporated in Delaware in February 2017. The company is a clinical-stage biopharmaceutical company developing treatments for rare, chronic and serious infectious diseases with unmet needs. The Company's initial drug candidate is epetraborole, which the Company is investigating as a potential once-daily oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacteria (" NTM ") pulmonary disease, a rare, chronic and progressive infectious disease caused by bacteria called mycobacteria that can cause irreversible lung damage and can be fatal.
Company Financials
EPS
ANTX has released its 2025 Q3 earnings. EPS was reported at -0.31, versus the expected -0.22, missing expectations. The chart below visualizes how ANTX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
